Florida Theranostics

Florida Theranostics is a clinical-stage biotechnology company focused on developing innovative radiopharmaceuticals for cancer diagnosis and therapy. Based in Gainesville, Florida, the company utilizes its proprietary Ethylenedicysteine (EC) platform to create targeted ligands for molecular imaging and radiotherapy. Their lead candidate, 99mTc-EC-G, targets glucose transporters and is designed to provide high-quality SPECT imaging as a cost-effective alternative to FDG-PET. The company's theranostic approach integrates these diagnostic tools with therapeutic counterparts labeled with isotopes like Rhenium-188. Florida Theranostics aims to improve global access to precision oncology by leveraging widely available SPECT technology. The company was founded by Dr. David J. Yang, a pioneer in radiopharmaceutical development.